HOME >> MEDICINE >> NEWS
New compound holds promise for lupus and related diseases

Ann Arbor, MI A chemical cousin of anti-anxiety medications, such as Valium and Xanax, significantly reduces kidney inflammation in mice inbred to develop a disease resembling human systemic lupus erythematosus (SLE), researchers at the University of Michigan and the University of California-Berkeley have found.

Their research, described in the Oct. 16 issue of the Journal of Clinical Investigation, also reveals the novel mechanism by which the compound works, a discovery that could lead to safer and more effective new drugs for managing lupus and other autoimmune disorders.

"The best available therapies for lupus haven't changed for many, many years," says U-M's Gary D. Glick, Ph.D., one of the lead authors on the study. "It's a disease where the mechanisms that normally prevent the immune system from attacking components of one's own body are defective. Because we do not yet understand what triggers lupus, it has been very difficult to develop lupus-specific therapies."

In fact, the mainstays of treating lupus-related kidney inflammation---the major cause of illness and death in lupus patients---are drugs developed many years ago to kill cancer cells. When given to lupus patients, often in combination with immune-suppressing steroids, these cytotoxic agents kill immune cells. But because they lack specificity, they also kill healthy cells, resulting in serious side effects. What's more, they simply are not effective in some patients.

"Our compound, on the other hand, goes in and kills the bad players but leaves the good players alone," says Glick, a charter faculty member of the U-M Life Sciences Institute, who is the Werner E. Bachmann Collegiate Professor of Chemistry, and a professor of biological chemistry in the U-M Medical School.

The compound, a 1,4-benzodiazepine (designated as Bz-423), sets off a chain of events that results in apoptosis, a natural cell-suicide process by which the body rids itself of cells
'"/>

Contact: Sally Pobojewski
pobo@umich.edu
734-615-6912
University of Michigan Health System
16-Oct-2002


Page: 1 2 3

Related medicine news :

1. New compounds effective against Alzheimers disease onset and progression
2. Marijuana-like compounds may aid array of debiliating conditions ranging from Parkinsons to pain
3. New compounds show promise in fighting malaria and cancer
4. Blueberry compound shows promise of lowering cholesterol as effectively as drug
5. New class of compounds promises to revive failing hearts
6. New compound may act to keep thyroid activity in check
7. Study finds certain compounds in beer, wine effective in slowing breast cancer cell growth
8. Researchers testing compounds that may stop replication of T-cell leukemia virus
9. Cocoa froths with cancer-preventing compounds
10. Alcohol may compound its damaging effects through frontocerebellar circuitry
11. Synthetic marijuana compound reduces agitation, improves appetite in Alzheimers patients

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: New compound holds promise for lupus and related diseases

(Date:4/21/2015)... 2015 Carinsurancesavings.biz has released a new blog ... surveillance and explaining the impact on a uto insurance ... and supervised may be eligible for advantageous auto insurance discounts. ... simple and efficient way. This will also help them get ... simple way. , Finding low cost coverage is no longer ...
(Date:4/21/2015)... 2015 Optimity Advisors ( Optimity), ... firm that helps clients in complex industries navigate ... the Association of Community Affiliated Plans ... represents 58 local, not-for-profit, community-affiliated Safety Net Health ... people primarily enrolled in public or state-sponsored coverage ...
(Date:4/21/2015)... CO (PRWEB) April 21, 2015 ... Management , a new knowledge management solution that ... and publishing of policies and procedures. With Quark ... create reusable content that is easy to save, ... is susceptible to risk and compliance issues. Examples ...
(Date:4/21/2015)... When a bandage sticks to an injury ... to solve this problem two inventors from Festus, Mo., ... bandage helps a cut, burn, abrasion or wound heal ... exposure. The bandage is easy to use, versatile and ... submitted to the St. Louis office of InventHelp. It ...
(Date:4/21/2015)... Ill. (PRWEB) April 21, 2015 The ... the late cosmetic dermatologist Fredric S. Brandt, M.D., by ... Dr. Brandt, an ASDS member since 1982, died earlier ... The funds are designed to provide opportunities for ASDS ... field of cosmetic dermatology that Dr. Brandt held so ...
Breaking Medicine News(10 mins):Health News:Auto Insurance Quotes Offer Excellent Security for A Car 2Health News:Optimity Advisors Named Preferred Vendor by the Association of Community Affiliated Plans (ACAP) 2Health News:Quark Software Inc. Introduces Procedure Management Solution for Global 2000 2Health News:Quark Software Inc. Introduces Procedure Management Solution for Global 2000 3Health News:ASDS honors the legacy of Dr. Fredric Brandt 2Health News:ASDS honors the legacy of Dr. Fredric Brandt 3Health News:ASDS honors the legacy of Dr. Fredric Brandt 4
(Date:4/21/2015)... 21, 2015 Asterias Biotherapeutics, Inc. (NYSE MKT: ... of regenerative medicine, today announced that the abstract describing ... from the Phase 2 clinical trial of the Company,s ... selected for an oral presentation at the 2015 American ... held in Chicago, Illinois May ...
(Date:4/20/2015)... 2015  Following is the daily "Profile America" feature ... MEDICINE Profile America — ... insulin —became available for general use this month in ... from diabetes. Insulin is a hormone produced by the ... in the human body. It was first isolated the ...
(Date:4/20/2015)... Ireland , April 20, 2015 ... that Charles M. Mayr , Chief Communications ... due to health reasons.  In conjunction with Mayr,s ... will assume the role of Chief Communications Officer, ... Kelly served as Senior Vice President, Chief Communications ...
Breaking Medicine Technology:Asterias Biotherapeutics Announces Phase 2 Clinical Data on Autologous Telomerase-based Dendritic Cell Cancer Vaccine AST-VAC1 Selected for Oral Presentation at the 2015 ASCO Annual Meeting 2Asterias Biotherapeutics Announces Phase 2 Clinical Data on Autologous Telomerase-based Dendritic Cell Cancer Vaccine AST-VAC1 Selected for Oral Presentation at the 2015 ASCO Annual Meeting 3U.S. Census Bureau Daily Feature for April 21 2Actavis Announces Retirement of Charles M. Mayr 2Actavis Announces Retirement of Charles M. Mayr 3
Cached News: